Antiviral drug Remdesivir to be applied in clinical trials Thursday

0 申博电子游戏Print E-mail Xinhua, February 6, 2020
Adjust font size:

The registration for clinical trials on the antiviral drug Remdesivir has been approved, and the first batch of pneumonia patients infected by the novel coronavirus (2019-nCoV) are expected to start taking the drug on Thursday, according to an official conference Wednesday.

Wang Chen (1st R), vice president of the Chinese Academy of Engineering and president of the Chinese Academy of Medical Sciences (CAMS), speaks at a conference in Wuhan, central China's Hubei Province, Feb. 5, 2020. The registration for clinical trials on the antiviral drug Remdesivir has been approved, and the first batch of pneumonia patients infected by the novel coronavirus (2019-nCoV) are expected to start taking the drug on Thursday, according to an official conference Wednesday. [Photo/Xinhua]

The approval is jointly supported by the Ministry of Science and Technology (MOST), the National Health Commission and the National Medical Products Administration.

Remdesivir is a drug developed by Gilead Sciences, an American pharmaceutical company, said Cao Bin, head of the drug's clinical trial program, at the conference held by the MOST at the Wuhan Jinyintan Hospital, central China's Hubei Province.

The drug has shown good antiviral activity against SARS and MERS coronavirus in previous cell and animal experiments. Its clinical trials against Ebola infections have been conducted abroad. In related domestic research, it has also shown fairly good antiviral activity against the 2019-nCoV at the cellular level, said Cao.

A total of 761 patients have been enrolled in the trials, which will adopt a randomized, double-blind and placebo-controlled study method.

The trials, led by the China-Japan Friendship Hospital and the Institute of Materia Medica under the Chinese Academy of Medical Sciences (CAMS), will be conducted in several hospitals in Wuhan, including the Wuhan Jinyintan Hospital.

Hopes have been pinned on the drug, but we have to wait for results of its actual effectiveness in the clinical trials, said Wang Chen, vice president of the Chinese Academy of Engineering and president of the CAMS. 

1   2   >  


Follow China.org.cn on Twitter and Facebook to join the conversation.
ChinaNews App Download

Go to Forum >>0 Comment(s)

No comments.

Add your comments...

  • User Name Required
  • Your Comment
  • Enter the words you see:    
    Racist, abusive and off-topic comments may be removed by the moderator.
网站地图 太阳城手机版 ag真人娱乐 极速百家乐 澳门新葡京赌场
www.988msc.com 申博娱乐 申博代理管理网手机登入 申博太阳城游戏帐号
777老虎机游戏 极速百家乐 申博娱乐开户 申博娱乐手机版
申博娱乐手机登入 ag真人娱乐 百家乐娱乐登入 太阳城集团
777老虎机游戏登入 申博太阳城直营网 盛618网址 申博现金网址